The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.
Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.
The collaboration will give the company access to UCI research in diagnostic platforms, life science applications, devices, and data analytics.
With European Union funds, the firm is accelerating its go-to-market strategy for the PrePsia four-metabolite, mass spec-based blood test for preterm preeclampsia.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
The firm said that the push toward outcomes-based medicine will drive innovation in diagnostic wearables and smart textiles over the next few years.
The funding will support manufacturing of the firm's Idylla PCR-based diagnostics platform and worker training at its Mechelen, Belgium facility.